FX.co ★ Silo Pharma Study Of SPC-15 Shows Potential For Depressive, Stress-Related Disorders

Silo Pharma, Inc. (SILO) has announced encouraging outcomes from its pre-clinical study of SPC-15. This study suggests that SPC-15 may be effective in treating major depressive disorder and other severe stress-related conditions.

The research, conducted using animal models, revealed that SPC-15, a 5-HT4R agonist combined with an NMDAR antagonist, might enhance treatment efficacy for severe conditions compared to the use of each agent independently. The dual therapy resulted in a notable decrease in stress-related behaviors in the animal subjects.

Silo Pharma intends to advance the development of SPC-15 as a preventive intranasal treatment option for PTSD.